BioInformant

Your Global Leader in Stem Cell Market Research

Home » Interviews » Page 2

BioInformant's Founder, Cade Hildreth, has interviewed hundreds of key opinion leaders (KOL's) from across the stem cell industry.

Cord Blood Banking in Latin America – Interview with James Mendez of Cryoholdco

By Leave a Comment

In this interview with James Alexis Mendez, we discuss the market strategy of CryoHoldco, a stem cell bank holding company that is the market leader in Latin America and one of the ten largest cord blood banks in the world. James Alexis Mendez currently serves as the CFO and Board member of CryoHoldco.

Approaching 200,000 stem cell units in storage, CryoHoldco is more than 5X larger than any other stem cell bank in Latin America. CryoHoldco owns the cord blood market leaders in both Mexico and Colombia, and plans to expand into other regions of Latin America. [Read more…]

Breakthrough Solutions for Human Primary Cells & Hematologic Tissue Products

By Leave a Comment

AllCells AllCells is a biotechnology company that specializes in biologically relevant, high quality primary cells to enable drug discovery, development, and manufacturing of cell therapies. Leveraging its expertise in hematological and immune cell isolations, combined with on-site whole blood and bone marrow tissue collection operations, AllCells maintains one of the world’s largest and most diverse repositories of donor profiles that can be screened and qualified for biomedical applications.

I had the honor of interviewing Dr. Jay Tong, President and CEO of AllCells. In this interview, we discuss AllCells history, its leadership in blood donor cell collections and hematologic tissue products and the recent opening of its newest facility in Boston, Massachusetts. We also explore the company’s long-term goals and expansion into the cell therapy development space. [Read more…]

Dr. Chris Centeno, Visionary Behind Regenexx® Stem Cell Technology

By Leave a Comment

Dr. Chris Centeno | Interview with Dr. Chris Centeno, Visionary Behind Regenexx® Stem Cell Technology
Dr. Chris Centeno, Visionary Behind Regenexx Technology

Dr. Chris Centeno is an international expert in regenerative medicine and the clinical use of mesenchymal stem cells (MSCs) for orthopedic applications. This is Part 2 of an interview with Dr. Centeno.

Read Part 1 of the interview here.

ACL Surgeries and Regenexx Stem Cell Technology

Dr. Centeno specializes in clinical use of adult stem cells for orthopedic injuries, which he treats through same-day procedures at his clinic in Denver, Colorado, and through cultured expansion of mesenchymal stem cells at a clinic in Grand Cayman. He first performed these adult stem cell procedures in the U.S. in 2005-2006, and his clinic has since has treated thousands orthopedic patients with stem cell based therapies.

Dr. Chris Centeno is best known for the Regenexx® technology, an approach that uses needle-based procedures coupled with sophisticated guidance techniques to place large numbers of stem cells at the site needing repair. This approach can often replace the need for invasive orthopedic surgeries. [Read more…]

Regenexx – Dr. Chris Centeno on the Orthopedic Applications of MSCs

By 1 Comment

Dr. Chris Centeno, CEO of Regenexx
Dr. Chris Centeno, Founder and CEO of Regenexx

Regenexx is a U.S. company specializing in orthopedic applications of stem cells that was founded by Dr. Chris Centeno. Dr. Centeno is an international expert in regenerative medicine and the clinical use of mesenchymal stem cells (MSCs) in orthopedic applications. His Regenexx clinic in Denver, Colorado, incorporates a variety of regenerative approaches, drawing patients from all over the U.S. who are seeking innovative, non-surgical treatments. [Read more…]

Hemostemix. The Canadian Biotech that Could Change Healthcare as We Know It.

By 2 Comments

Hemostemix Inc. (“Hemostemix”) (TSX Venture:HEM; OTCQB:HMTXF) is a publicly traded  clinical-stage biotech company that develops and commercializes blood-derived stem cell therapies for medical conditions lacking adequate treatment options. Importantly, it is one of the first clinical-stage biotech companies to test a stem cell therapy within an international, multi-center Phase II clinical trial for patients with critical limb ischemia (“CLI”). CLI is a severe form of peripheral artery disease (“PAD”) that is caused by reduced blood flow to the extremities. [Read more…]

BioInformant's World-Class Clients